Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH

Loomba, Rohit; J. Sanyal, Arun; V. Kowdley, Kris; L. Bhatt, Deepak; Alkhouri, Naim; P. Frías, Juan; Bédossa, Pierre; A. Harrison, Stephen; J. Lazas, Donald; J. Barish, Robert; D. Gottwald, Mildred; Feng, Shibao; D. Agollah, Germaine; L. Hartsfield, Cynthia; Mansbach, Hank; Margalit, Maya; F. Abdelmalek, Manal

doi:10.1056/nejmoa2304286

Public

Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH

Published in New England Journal of Medicine • Jun 24, 2023

Authors:

Rohit Loomba

Arun J. Sanyal

Kris V. Kowdley

Abstract

BACKGROUND: Pegozafermin is a long-acting glycopegylated (pegylated with the use of site-specific glycosyltransferases) fibroblast growth factor 21 (FGF21) analogue in development for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia. The efficacy and safety of peg...

Subject

FGF21

Randomized controlled trial

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!